Peter Adamson, MD, Pediatric Hematology & Oncology, Cambridge, MA


Pediatric Hematology & Oncology Cambridge, MA

Global Head, Oncology Development & Pediatric Innovation, Sanofi

Dr. Adamson is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Adamson's full profile

Already have an account?

Education & Training

  • NIH Clinical CtrFellowship, Biotechnology, 1990 - 1992
  • NIH Clinical CtrFellowship, 1987 - 1990
  • Children's Hospital of Philadelphia
    Children's Hospital of PhiladelphiaResidency, Pediatrics, 1984 - 1987
  • Weill Cornell Medical College of Cornell University
    Weill Cornell Medical College of Cornell UniversityClass of 1984
  • Wesleyan UniversityBA, Chemistry, 1976 - 1980

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 1988 - 2000
  • PA State Medical License
    PA State Medical License 1986 - 2022
  • American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2008-2014
  • America's Top Doctors for Cancer Castle Connolly, 2006-2013
  • Philadelphia Magazine Castle Connolly, 2006-2008, 2010-2012
  • Join now to see all

Clinical Trials

Publications & Presentations


Journal Articles

  • Acute pancreatitis following ifosfamide.  
    Izraeli S, Adamson PC, Blaney SM, Balis FM, Cancer; 74(5):1627-1628
  • A phase I trial of amifostine (WR-2721) and melphalan in pediatric patients with advanced neoplastic disease.  
    Adamson PC, Balis FM, Belasco JE, Lange B, Berg SL, Blaney SM, Craig C, Poplack DG, Cancer Res; 55:4069-4072
  • Pharmacokinetics of 9-cis-retinoic acid in the rhesus monkey.  
    Adamson PC, Murphy RF, Godwin KA, Ulm EH, Balis FM, Cancer Res; 55(3):482-485
  • Join now to see all

Books/Book Chapters

  • Join now to see all


  • Phase I study of sorafenib in children with refractory solid tumors: A Children's Oncology Group Phase I Consortium trial.
    Widemann BC, Fox E, Adamson PC, Baruchel S, Kim A, Ingle AM, Bender JG, Stempak D, Balis FM, Blaney SM, ASCO Meeting Abstracts
  • Modeling MLN8237, an aurora kinase a inhibitor, with irinotecan (IRN) and temozolomide (TMZ) in neuroblastoma (NB).
    Lipsitz EG, Nguyen V, Zhao H, Ecsedy J, Maris JM, Adamson PC, Mosse YP, ASCO Meeting Abstracts; 28(15_suppl):10593. PMID
  • A pediatric phase I trial and pharmacokinetic study of MLN8237, an oral selective small molecule inhibitor of aurora a kinase: A Children's Oncology Group Phase I Cons...
    Mosse YP, Lipsitz EG, Maris JM, Weigel B, Adamson PC, Ingle M, Ahern CH, Blaney S, ASCO Meeting Abstracts; 28(15_suppl):9529
  • Join now to see all


  • Early Phase Cancer Drug Development in Children. 
    Philadelphia, PA, 2007; Boulder, CO, 2008
  • Development of Targeted Therapy for Children with Cancer. 
    Ely Brent Visiting Professor The Children’s Hospital, Denver Cancer Center Rounds
  • New Agents for Children with Cancer. 
    Pediatric Grand Rounds, Denver, CO
  • Join now to see all

Press Mentions

  • Additional Pediatric Cancer Funding in the Offing?
    Additional Pediatric Cancer Funding in the Offing?April 05, 2019 16:34
  • Niraparib Shrinks BRCA-Mutated Prostate Tumors
    Niraparib Shrinks BRCA-Mutated Prostate TumorsApril 05, 2019 16:34
  • Blue Ribbon Panel Announced to Help Guide Vice President Biden’s National Cancer Moonshot Initiative
    Blue Ribbon Panel Announced to Help Guide Vice President Biden’s National Cancer Moonshot InitiativeApril 05, 2016 03:46
  • Join now to see all